Study links Bacillus amyloliquefaciens to better Zi goose gut health

A newly published study in Animals examines whether dietary Bacillus amyloliquefaciens can help growing Zi geese perform better without relying on antibiotic growth promoters, and the answer appears to be yes, at least under the study conditions. According to the paper, supplementation improved growth performance alongside immune performance, antioxidant capacity, intestinal morphology, jejunal microbiota, and intestinal transcriptomic profiles, adding a multi-layered dataset to a part of poultry nutrition that has far less evidence in geese than in broilers. (mdpi.com)

The backdrop is familiar across food-animal medicine: pressure to reduce routine antibiotic growth-promoter use has accelerated interest in probiotics as nutritional tools that might support gut integrity, immune balance, and feed efficiency. In broilers, B. amyloliquefaciens has repeatedly been studied as an antibiotic alternative, with reports of improved antioxidant activity, digestive function, barrier integrity, and microbiota modulation. But goose-specific evidence has lagged, which makes Zi goose data more notable than a routine probiotic paper might suggest. (frontiersin.org)

That context matters because geese are not just smaller broilers. Their feeding behavior, gut physiology, and production systems differ, and recent goose studies have explored a range of nutritional strategies, from herbal additives to organic acids and other probiotics, to improve performance through intestinal and microbial pathways. For example, recent work in Zi geese and other goose lines has linked dietary interventions with stronger antioxidant enzyme activity, improved villus-to-crypt ratios, and shifts away from potentially less favorable microbial profiles. (pubmed.ncbi.nlm.nih.gov)

In the new Zi goose study, the authors specifically focused on growth, immunity, antioxidant status, jejunal microbiota, and transcriptomics, rather than limiting the work to body weight and feed conversion. That broader design fits with how the probiotic field has evolved. Earlier poultry studies of B. amyloliquefaciens have suggested the organism may work not through a single mechanism, but through several overlapping ones, including reduced oxidative stress, altered inflammatory signaling, improved epithelial barrier function, and microbial reshaping. Similar transcriptomic work in broilers found probiotic supplementation was associated with downregulation of immune-response pathways in the ileum, which researchers interpreted as a sign of reduced intestinal inflammatory burden and more efficient nutrient use. (pubmed.ncbi.nlm.nih.gov)

I didn’t find a separate institutional press release or substantial outside expert commentary tied specifically to this Zi goose paper. What I did find was a broader industry-science consensus in the literature: Bacillus-based probiotics remain promising, but outcomes are inconsistent across strains and production settings. A review in Animal Production Science notes that probiotic benefits in poultry can be meaningful, but not always uniform, while broiler studies with B. amyloliquefaciens continue to report positive effects on oxidative status and intestinal health under controlled conditions. That makes this goose study directionally consistent with the field, even if it doesn’t settle the question of how well the findings will travel to commercial use. (doi.org)

Why it matters: For veterinarians, nutritionists, and technical service teams, the practical value here is less about one probiotic species “winning” and more about the kind of evidence being assembled. A study that combines performance data with immune, antioxidant, microbiota, and transcriptome readouts gives a stronger biological rationale for probiotic use than simple weight-gain results alone. In goose production, where published evidence is comparatively sparse, that can help inform feed-additive discussions with integrators and pet parents involved in small-scale or specialty waterfowl production, especially when antibiotic-reduction goals are part of the conversation. But the caution is important: probiotic efficacy is highly strain-specific, and published benefits in one B. amyloliquefaciens product, dose, or species should not be assumed for another. (efsa.onlinelibrary.wiley.com)

There’s also a regulatory and commercial reality underneath the science. Safety and efficacy assessments for Bacillus amyloliquefaciens feed additives have existed for years in some poultry contexts, including EFSA review of products for chickens for fattening, but that doesn’t automatically translate to every formulation, market, or species. Veterinary professionals evaluating these products still need to ask basic questions: Which strain? What viable count? What inclusion rate? What endpoint was actually improved, and in what production environment? (efsa.onlinelibrary.wiley.com)

What to watch: The next meaningful developments will be replication in larger and more commercial goose cohorts, clearer reporting on strain identity and dosing, and, ideally, comparative studies against other non-antibiotic tools already being tested in geese. If those data hold up, B. amyloliquefaciens could move from “promising probiotic” to a more evidence-backed component of goose nutrition programs. (pubmed.ncbi.nlm.nih.gov)